Altamira Therapeutics Ltd (CYTO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-1992 | 12-1991 | 12-1990 | 12-1989 | 12-1988 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -12,939 | -15,344 | -17,339 | -13,956 | -17,821 |
| Depreciation Amortization | 1,690 | 1,052 | 1,053 | 690 | 1,360 |
| Other Working Capital | -6,051 | -394 | -1,799 | 852 | 5,927 |
| Other Operating Activity | -152 | -274 | -155 | -79 | 0 |
| Operating Cash Flow | $-17,452 | $-14,960 | $-18,240 | $-12,493 | $-10,534 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -3,370 | -877 | -1,950 | -1,736 | N/A |
| Net Acquisitions | N/A | N/A | N/A | 5 | N/A |
| Other Investing Activity | 12,689 | -11,864 | -22,596 | 9,436 | -7,344 |
| Investing Cash Flow | $9,319 | $-12,741 | $-24,546 | $7,705 | $-7,344 |
| Cash Flows From Financing Activities | |||||
| Dividend Paid | -1,724 | -1,725 | -1,457 | N/A | N/A |
| Other Financing Activity | 3,778 | 32,233 | 32,532 | 16,350 | 6,270 |
| Financing Cash Flow | $2,054 | $30,508 | $31,075 | $16,350 | $6,270 |
| Beginning Cash Position | 8,956 | 6,149 | 17,860 | 6,298 | 38,426 |
| End Cash Position | 2,877 | 8,956 | 6,149 | 17,860 | 26,818 |
| Net Cash Flow | $-6,079 | $2,807 | $-11,711 | $11,562 | $-11,608 |
| Free Cash Flow | |||||
| Operating Cash Flow | -17,452 | -14,960 | -18,240 | -12,493 | -10,534 |
| Free Cash Flow | -17,452 | -14,960 | -18,240 | -12,493 | -10,534 |